Cholecalciferol for prophylaxis against antituberculosis therapy-induced liver disorders among naïve patients with pulmonary tuberculosis: A randomized, comparative study
Hasanain AFA, Zayed AAH, Mahdy RE, Nafee AMA
International journal of mycobacteriology · 11 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2017-01-01 · Int J Mycobacteriol · vol. 6 · issue 2 · p. 149
- Publisher
- Elsevier BV
- Cited
- 13 citations · more than 78% of similar papers · 1.1× the field average
- References
- 35 works
- Access
- Open access (free to publish) · CC-BY-NC-SA
- Research areas
- Drug-Induced Hepatotoxicity and Protection · Tuberculosis Research and Epidemiology · Hepatitis C virus research
- Keywords
- Medicine, Internal medicine, Gastroenterology, Incidence (geometry), Adverse effect, Tuberculosis, Cholecalciferol, vitamin D deficiency, Population, Vitamin D and neurology, Pathology
- MeSH
- liver, humans, tuberculosis, pulmonary, cholecalciferol, antitubercular agents, prospective studies, adult, middle aged, female, male, young adult, chemical and drug induced liver injury
4 authors
From EG
- AhmadFarooq Alsayed Hasanain · correspondingAssiut University
- AliAbdel-Azeem Hasan ZayedAssiut University
- ReemEzzat MahdyAssiut University
- AmanyMohamed Adawi NafeeAssiut University
Abstract
Background
Patients in countries endemic for chronic viral hepatitis are more vulnerable to antituberculosis therapy-induced liver disorders (ATT-LDs). The aim of this study was to explore the role of cholecalciferol in prophylaxis against ATT-LD among patients with pulmonary tuberculosis (TB) receiving ATT.
Material and methods
We conducted a hospital-based, prospective, randomized, comparative study which included 300 consecutive, naïve patients with pulmonary TB eligible for ATT. The patients were randomly allocated to Group A (150 patients who received ATT) and Group B (150 patients who received ATT with cholecalciferol) who had clinical evaluation, laboratory investigations, and imaging studies. Statistical analysis used student's t-test and Chi-square test were used as appropriate to compare the variables between the study groups.
Results
The study population mean age was 35.6 ± 15.3 years. The overall incidence rate of ATT-LD among the study population was 9.3%; the incidence rate was significantly higher among Group A patients compared to those of Group B (13.3 vs. 5.3%;P = 0.001). The onset of ATT-LD was significantly earlier among patients of Group A compared to those of Group B (31.4 vs. 58.7 days,P = 0.027), while the duration of ATT-LD was significantly longer among patients of Group A compared to those of Group B (34.8 vs. 16.9 days,P = 0.009). No adverse effects related to cholecalciferol use were observed.
Conclusions
Adjuvant cholecalciferol supplementation may be protective against ATT-LD without extra adverse effects. Before recommending the routine use of cholecalciferol supplementation for prevention of ATT-LD, larger scale studies are recommended.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.